Arcus Biosciences, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+2.27%
vs ±11.2% implied · ×0.20
shaded = implied · ▲▼ = realized
No thesis.
Arcus Biosciences, Inc.
18.19
−0.42 · −2.27%
post 18.19 0.00%
Fund move
Fund move
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | Gilead SciencesGilead Sciences | $968.8M | 25.52% | 0.00% | |
| 2 | BlackRockBlackRockindex-like | $506.1M | 13.33% | +7.81% | |
| 3 | State StreetState Streetindex-like | $185.9M | 4.90% | +11.39% | |
| 4 | Wellington Management GroupWellington | $181.8M | 4.79% | −3.19% | |
| 5 | Suvretta Capital ManagementSuvretta | $147.3M | 3.88% | −5.06% | |
| 6 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $138.0M | 3.63% | +4.76% | |
| 7 | FMRFMR | $124.9M | 3.29% | +247.54% | |
| 8 | Vanguard Capital ManagementVanguardindex-like | $119.9M | 3.16% | +0.82% | |
| 9 | Citadel AdvisorsCitadel | $97.5M | 2.57% | +122.63% | |
| 10 | Woodline PartnersWoodline Partners | $92.7M | 2.44% | −20.38% | |
| 11 | Geode Capital ManagementGeodeindex-like | $75.5M | 1.99% | +8.72% | |
| 12 | SirenSiren | $74.6M | 1.97% | −19.51% | |
| 13 | Fisher Asset ManagementFisher | $66.0M | 1.74% | −2.33% | |
| 14 | Marshall WaceMarshall Wace | $60.0M | 1.58% | −48.29% | |
| 15 | Samlyn CapitalSamlyn Capital | $47.7M | 1.26% | −18.93% | |
| 16 | Dimensional Fund AdvisorsDimensional | $44.2M | 1.16% | +0.57% | |
| 17 | BNP Paribas Investment PartnersBNP Paribas Investment Partners | $43.8M | 1.15% | −14.21% | |
| 18 | Goldman Sachs GroupGoldman Sachs | $42.8M | 1.13% | +38.79% | |
| 19 | Soleus Capital ManagementSoleus | $36.0M | 0.95% | +158.58% | |
| 20 | Sofinnova InvestmentsSofinnova | $29.2M | 0.77% | +2.45% | |
| 21 | Charles Schwab Investment ManagementCharles Schwabindex-like | $29.0M | 0.76% | +4.22% | |
| 22 | Northern TrustNorthern Trustindex-like | $28.7M | 0.76% | +10.97% | |
| 23 | Parkman Healthcare PartnersParkman Healthcare Partners | $28.3M | 0.75% | −23.86% | |
| 24 | InvescoInvesco | $26.1M | 0.69% | +2.97% | |
| 25 | Baker Bros. AdvisorsBaker Bros. | $26.0M | 0.69% | +103.27% |
232 managers report $3.8B of Arcus Biosciences on form 13F for the quarter ended Jun 30 '26. 19 of them hold 80% of it; Gilead Sciences is largest at 25.52%.
Linked news
Expected move
No implied move.
No implied move.
No implied move.